Literature DB >> 24894771

Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency.

Anne Rensing-Ehl1, Simon Völkl2, Carsten Speckmann3, Myriam Ricarda Lorenz4, Julia Ritter5, Ales Janda3, Mario Abinun6, Hanspeter Pircher7, Bertram Bengsch8, Robert Thimme8, Ilka Fuchs1, Sandra Ammann1, Andrea Allgäuer2, Karim Kentouche9, Andrew Cant6, Sophie Hambleton6, Claudia Bettoni da Cunha10, Sebastian Huetker11, Ingrid Kühnle11, Arnulf Pekrun12, Markus G Seidel13, Michael Hummel5, Andreas Mackensen2, Klaus Schwarz14, Stephan Ehl3.   

Abstract

Accumulation of CD3(+) T-cell receptor (TCR)αβ(+)CD4(-)CD8(-) double-negative T cells (DNT) is a hallmark of autoimmune lymphoproliferative syndrome (ALPS). DNT origin and differentiation pathways remain controversial. Here we show that human ALPS DNT have features of terminally differentiated effector memory T cells reexpressing CD45RA(+) (TEMRA), but are CD27(+)CD28(+)KLRG1(-) and do not express the transcription factor T-bet. This unique phenotype was also detected among CD4(+) or CD8(+) ALPS TEMRA cells. T-cell receptor β deep sequencing revealed a significant fraction of shared CDR3 sequences between ALPS DNT and both CD4(+) and CD8(+)TEMRA cells. Moreover, in ALPS patients with a germ line FAS mutation and somatic loss of heterozygosity, in whom biallelic mutant cells can be tracked by absent Fas expression, Fas-negative T cells accumulated not only among DNT, but also among CD4(+) and CD8(+)TEMRA cells. These data indicate that in human Fas deficiency DNT cannot only derive from CD8(+), but also from CD4(+) T cells. Furthermore, defective Fas signaling leads to aberrant transcriptional programs and differentiation of subsets of CD4(+) and CD8(+) T cells. Accumulation of these cells before their double-negative state appears to be an important early event in the pathogenesis of lymphoproliferation in ALPS patients.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24894771     DOI: 10.1182/blood-2014-03-564286

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.

Authors:  Christian Klemann; Myrian Esquivel; Aude Magerus-Chatinet; Myriam R Lorenz; Ilka Fuchs; Nathalie Neveux; Martin Castelle; Jan Rohr; Claudia Bettoni da Cunha; Martin Ebinger; Robin Kobbe; Bernhard Kremens; Florian Kollert; Eleonora Gambineri; Kai Lehmberg; Markus G Seidel; Kathrin Siepermann; Thomas Voelker; Volker Schuster; Sigune Goldacker; Klaus Schwarz; Carsten Speckmann; Capucine Picard; Alain Fischer; Frederic Rieux-Laucat; Stephan Ehl; Anne Rensing-Ehl; Benedicte Neven
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941

2.  Live and let die at TEMRA.

Authors:  Frédéric Rieux-Laucat
Journal:  Blood       Date:  2014-08-07       Impact factor: 22.113

Review 3.  The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.

Authors:  Frédéric Rieux-Laucat; Aude Magérus-Chatinet; Bénédicte Neven
Journal:  J Clin Immunol       Date:  2018-06-17       Impact factor: 8.317

Review 4.  Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).

Authors:  Markus G Seidel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.

Authors:  Lindsey A George; David T Teachey
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

Review 6.  Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.

Authors:  Markus G Seidel
Journal:  Blood       Date:  2014-08-27       Impact factor: 22.113

7.  Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Seiji Yokoyama; Pin-Yu Perera; Seigo Terawaki; Nobumasa Watanabe; Osamu Kaminuma; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

8.  Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens.

Authors:  Giovanna Flores-Mendoza; Noé Rodríguez-Rodríguez; Rosa M Rubio; Iris K Madera-Salcedo; Florencia Rosetti; José C Crispín
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

Review 9.  Double-negative T cells in autoimmune diseases.

Authors:  Hao Li; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2021-03-01       Impact factor: 4.941

10.  Mouse models of lupus: what they tell us and what they don't.

Authors:  Mara Lennard Richard; Gary Gilkeson
Journal:  Lupus Sci Med       Date:  2018-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.